Brought to you by 
Stendhal gets rights to Helsinn's cachexia-anorexia compound anamorelin
01 Mar 2013
Executive Summary
Mexican pharmaceuticals company Especificos Stendhal SA de CV (Standhal) has licensed exclusive rights to sell Helsinn Group’s ghrelin receptor agonist anamorelin for cachexia and anorexia in non-small cell lung cancer patients in Mexico, Venezuela, Colombia, Peru, Ecuador, and most of Central America.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Stendhal gets rights to Helsinn's cachexia-anorexia compound anamorelin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice